• YD Bio posted a net loss of USD 8.31 million for fiscal 2025, widening from a net loss of USD 1.41 million a year earlier.
• Revenue rose 17% to USD 596,817.
• Operating loss widened to USD 5.27 million from USD 1.46 million.
• Cash and cash equivalents climbed to USD 6 million from USD 3.1 million, following a PIPE financing that secured USD 13.2 million in gross proceeds.
• For 2026, YD Bio forecast USD 2.4 million to USD 2.7 million of operating cash needs and USD 9 million to USD 10 million of capital expenditures, primarily tied to real estate and production-facility investment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-050282), on April 30, 2026, and is solely responsible for the information contained therein.